Axsome Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 28, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
August 08, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
Interim analysis results from two Phase 3 trials and topline results from one Phase 2 trial of AXS-05 anticipated in 4Q 2018 Phase 3 trial of AXS-07 in acute migraine anticipated to start in 4Q 2018 ...
Axsome Therapeutics to Report Second Quarter 2018 Financial Results on August 8, 2018
August 01, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Wednesday, August 8, 2018 at 8:00 AM Eastern Time NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer’s Association International Conference
July 17, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder
June 05, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
First patient enrolled in the ASCEND study Trials in two mood disorders now underway with AXS-05 NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a...
Axsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual Meeting
May 29, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics to Present at the 2018 BIO International Convention
May 22, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
May 08, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association
May 03, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018
May 01, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Tuesday, May 8, 2018 at 8:00 AM Eastern Time NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage...